These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36160244)

  • 1. The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance.
    Wang Y; Huang L; Huang T; Geng S; Chen X; Huang X; Lai P; Du X; Weng J
    Front Microbiol; 2022; 13():813576. PubMed ID: 36160244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
    Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
    Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
    J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
    Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
    Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
    Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
    PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
    Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
    Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yanning Syrup ameliorates the lipopolysaccharide-induced inflammation: Adjusting the gut microbiota, short-chain fatty acids, and the CD4
    Wei D; Ma P; Fan Q; Yu H; Peng Y; Li X
    J Ethnopharmacol; 2022 Jan; 283():114729. PubMed ID: 34634365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD.
    Lai P; Chen X; Guo L; Wang Y; Liu X; Liu Y; Zhou T; Huang T; Geng S; Luo C; Huang X; Wu S; Ling W; Du X; He C; Weng J
    J Hematol Oncol; 2018 Dec; 11(1):135. PubMed ID: 30526632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
    Fransolet G; Ehx G; Somja J; Delens L; Hannon M; Muller J; Dubois S; Drion P; Caers J; Humblet-Baron S; Delvenne P; Beguin Y; Conteduca G; Baron F
    J Hematol Oncol; 2016 Jul; 9(1):53. PubMed ID: 27377819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
    Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
    Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease
    Han L; Jin H; Zhou L; Zhang X; Fan Z; Dai M; Lin Q; Huang F; Xuan L; Zhang H; Liu Q
    Front Immunol; 2018; 9():669. PubMed ID: 29740427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells.
    Hotta M; Yoshimura H; Satake A; Tsubokura Y; Ito T; Nomura S
    Eur J Immunol; 2019 Jan; 49(1):179-191. PubMed ID: 30457669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
    Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host-disease in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease.
    Sonntag K; Eckert F; Welker C; Müller H; Müller F; Zips D; Sipos B; Klein R; Blank G; Feuchtinger T; Schumm M; Handgretinger R; Schilbach K
    J Autoimmun; 2015 Aug; 62():55-66. PubMed ID: 26143958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation.
    Gao MG; Hong Y; Zhao XY; Pan XA; Sun YQ; Kong J; Wang ZD; Wang FR; Wang JZ; Yan CH; Wang Y; Huang XJ; Zhao XS
    Front Immunol; 2021; 12():720354. PubMed ID: 34539656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
    Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
    Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Körholz D; Kunst D; Hempel L; Söhngen D; Heyll A; Bönig H; Göbel U; Zintl F; Burdach S
    Bone Marrow Transplant; 1997 Apr; 19(7):691-5. PubMed ID: 9156246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.